Clinical Trials Browser

Phase 2 × Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer × 90 days × Clear all

NCT05297890 2025-12-23

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer